It is now well-accepted that neuroinflammation contributes significantly to the pathogenesis of Alzheimer´s disease (AD) and related cerebral proteopathies. However, little is known about how brain inflammatory states are reflected by molecular biomarker changes in bodily fluids. We have identified a panel of 25 proteins in cerebrospinal fluid (CSF) that may capture the neuroinflammatory states in AD patients. In this project, we aim to validate this protein panel and test the panel in well-characterized AD patient cohorts. The ultimate goal is to develop a multiplex immunoassay for these CSF proteins to assess human neuroinflammatory brain states in AD and related proteopathies.